ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
Bpharma
|
124 |
41K |
8 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
124
|
41K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
Bpharma
|
124 |
41K |
17 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
41K
|
17
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
Bpharma
|
124 |
41K |
1 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
41K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
Bpharma
|
124 |
41K |
13 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
41K
|
13
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Patients Update - Special Access Scheme
|
|
Bpharma
|
124 |
41K |
21 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
124
|
41K
|
21
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
0 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
0
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
Bpharma
|
7 |
2.7K |
1 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
7
|
2.7K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Australian Patent Granted for RECCE Anti-Infectives
|
|
Bpharma
|
5 |
2.2K |
5 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
5
|
2.2K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
45 |
13K |
2 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
45
|
13K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
45 |
13K |
5 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
45
|
13K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
45 |
13K |
2 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
45
|
13K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce's US leaders Down Under to drive R327 clinical trials
|
|
Bpharma
|
8 |
3.5K |
1 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
8
|
3.5K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
45 |
13K |
4 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
45
|
13K
|
4
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
2 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
2
|
|
ASX - By Stock
|
PVE |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
Bpharma
|
7 |
2.7K |
1 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
7
|
2.7K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Completes Cohort Dosing in Phase I/II UTI Trial
|
|
Bpharma
|
5 |
2.0K |
5 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
5
|
2.0K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce's US leaders Down Under to drive R327 clinical trials
|
|
Bpharma
|
8 |
3.5K |
8 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
8
|
3.5K
|
8
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Abstract & Poster Presentation at US Military Symposium
|
|
Bpharma
|
6 |
2.0K |
6 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
6
|
2.0K
|
6
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
1 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
1
|
|
ASX - By Stock
|
PVE |
Re:
Ann: PVE completes PM-1 Gas Plant Construction & Connections
|
|
Bpharma
|
25 |
9.6K |
1 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
25
|
9.6K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
|
|
Bpharma
|
25 |
7.5K |
0 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
25
|
7.5K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
|
|
Bpharma
|
25 |
7.5K |
0 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
25
|
7.5K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
|
|
Bpharma
|
25 |
7.5K |
6 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
25
|
7.5K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
|
|
Bpharma
|
25 |
7.5K |
4 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
25
|
7.5K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
|
|
Bpharma
|
25 |
7.5K |
3 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
25
|
7.5K
|
3
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Corporate Presentation
|
|
Bpharma
|
80 |
30K |
4 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
80
|
30K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Blindsided by results downgrade?
|
|
Bpharma
|
14 |
5.0K |
1 |
22/07/23 |
22/07/23 |
ASX - By Stock
|
14
|
5.0K
|
1
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Corporate Presentation
|
|
Bpharma
|
80 |
30K |
1 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
80
|
30K
|
1
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Corporate Presentation
|
|
Bpharma
|
80 |
30K |
0 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
80
|
30K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Blindsided by results downgrade?
|
|
Bpharma
|
14 |
5.0K |
14 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
14
|
5.0K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Clinical Trial Data Review Complete
|
|
Bpharma
|
31 |
8.6K |
9 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
31
|
8.6K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I Clinical Trial Data Review Complete
|
|
Bpharma
|
31 |
8.6K |
12 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
31
|
8.6K
|
12
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Corporate Presentation
|
|
Bpharma
|
80 |
30K |
2 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
80
|
30K
|
2
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Corporate Presentation
|
|
Bpharma
|
80 |
30K |
2 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
80
|
30K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First Cohort Dosed in Rapid Infusion Phase I/II UTI study
|
|
Bpharma
|
22 |
7.9K |
1 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
22
|
7.9K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE General Discussion Topics
|
|
Bpharma
|
51 |
26K |
1 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
51
|
26K
|
1
|
|
ASX - By Stock
|
JGH |
Re:
Ann: Jade Gas Continues to Intersect Significant Gassy Coal
|
|
Bpharma
|
2 |
1.6K |
1 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
2
|
1.6K
|
1
|
|
ASX - By Stock
|
PVE |
Re:
Ann: PVE completes PM-1 Gas Plant Construction & Connections
|
|
Bpharma
|
25 |
9.6K |
0 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
25
|
9.6K
|
0
|
|
ASX - By Stock
|
PVE |
Re:
Ann: PVE completes PM-1 Gas Plant Construction & Connections
|
|
Bpharma
|
25 |
9.6K |
0 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
25
|
9.6K
|
0
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
2 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
2
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
4 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
4
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
0 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
0
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
1 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
1
|
|
ASX - By Stock
|
JGH |
Re:
Ann: Jade Commences 2D Seismic Program at TTCBM Gas Project
|
|
Bpharma
|
5 |
2.6K |
3 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
5
|
2.6K
|
3
|
|
ASX - By Stock
|
PVE |
Re:
Ann: PVE completes PM-1 Gas Plant Construction & Connections
|
|
Bpharma
|
25 |
9.6K |
0 |
12/07/23 |
12/07/23 |
ASX - By Stock
|
25
|
9.6K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: First Cohort Dosed in Rapid Infusion Phase I/II UTI study
|
|
Bpharma
|
22 |
7.9K |
3 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
22
|
7.9K
|
3
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
1 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
1
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
1 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
1
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
5 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
5
|
|
ASX - By Stock
|
EUR |
Re:
EUROPEAN LITHIUM LIMITED
|
|
Bpharma
|
4.9K |
1.5M |
5 |
10/07/23 |
10/07/23 |
ASX - By Stock
|
4.9K
|
1.5M
|
5
|
|